Literature DB >> 24630034

Clinical treatment outcomes for 40 patients with bisphosphonates-related osteonecrosis of the jaws.

Li-Wan Lee1, Sheng-Huang Hsiao2, Li-Kai Chen3.   

Abstract

BACKGROUND/
PURPOSE: Bisphosphonates (BPs) are used to treat osteoporosis and bone metastases from malignancy. They may result in BPs-related osteonecrosis of the jaws (BRONJ) in a subset of patients receiving BPs. This study examined whether conservative or aggressive surgical approach could result in successful treatment of BRONJ lesions and assessed whether concomitant steroid administration or tobacco smoking habit might hinder the remission of BRONJ lesions.
METHODS: The 40 BRONJ patients were evenly divided into four different groups. Group 1 contained 10 patients with concomitant corticosteroid medication but without smoking habit. Group 2 contained 10 patients with smoking habit but without concomitant corticosteroid medication. Groups 3 and 4 each consisted of 10 patients without concomitant corticosteroid medication and smoking habit. To avoid bias, each group contained equal number of patients with different stages of BRONJ. Patients in Groups 1, 2, and 3 received conservative treatment, including antibiotic coverage, antibacterial solution irrigation, and minor surgical debridement. Patients in Group 4 were treated with aggressive surgical excision of necrotic bone segment.
RESULTS: The mean duration to achieve complete remission of BRONJ lesion was 19.7±0.6, 18.2±0.5, 13.0±1.0, and 7.6±1.1 months for patients in Groups 1, 2, 3 and 4, respectively. Student's t-test showed significant differences in the mean duration to achieve complete remission of BRONJ lesion between Groups 1 and 3, between Groups 2 and 3, between Groups 3 and 4, between Groups 1 and 4, and between Groups 2 and 4 (all p values < 0.001).
CONCLUSION: Although both conservative and aggressive surgical approaches can result in successful treatment of BRONJ lesions, aggressive surgical treatment needs a shorter mean duration to achieve complete remission of BRONJ lesion than conservative treatment. Concomitant corticosteroid administration or tobacco smoking may prolong the duration for complete remission of BRONJ lesion.
Copyright © 2012. Published by Elsevier B.V.

Entities:  

Keywords:  aggressive treatment; bisphosphonate; conservative treatment; corticosteroid; osteonecrosis; tobacco

Mesh:

Substances:

Year:  2012        PMID: 24630034     DOI: 10.1016/j.jfma.2012.04.010

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  7 in total

Review 1.  Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ).

Authors:  Victoria Rollason; Alexandra Laverrière; Laura C I MacDonald; Tanya Walsh; Martin R Tramèr; Nicole B Vogt-Ferrier
Journal:  Cochrane Database Syst Rev       Date:  2016-02-26

Review 2.  Interventions for managing medication-related osteonecrosis of the jaw.

Authors:  Natalie H Beth-Tasdogan; Benjamin Mayer; Heba Hussein; Oliver Zolk; Jens-Uwe Peter
Journal:  Cochrane Database Syst Rev       Date:  2022-07-12

3.  The Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review with a Pooled Analysis of Only Surgery versus Combined Protocols.

Authors:  Olga Di Fede; Federica Canepa; Vera Panzarella; Rodolfo Mauceri; Carmine Del Gaizo; Alberto Bedogni; Vittorio Fusco; Pietro Tozzo; Giuseppe Pizzo; Giuseppina Campisi; Antonio Galvano
Journal:  Int J Environ Res Public Health       Date:  2021-08-10       Impact factor: 3.390

Review 4.  Surgical management of bisphosphonate-related osteonecrosis of the jaws: literature review.

Authors:  Larissa Fernandes Silva; Cláudia Curra; Marcelo Salles Munerato; Carlos Cesar Deantoni; Mariza Akemi Matsumoto; Camila Lopes Cardoso; Marcos Martins Curi
Journal:  Oral Maxillofac Surg       Date:  2015-12-11

5.  Submental Perforator Flap for Soft-Tissue Reconstruction in Bisphosphonate-Related Osteonecrosis of the Jaws.

Authors:  Jose-Antonio García-de Marcos; Juan Rey-Biel
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2016-11-01

6.  Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307).

Authors:  Darya A Kizub; Jieling Miao; Mark M Schubert; Alexander H G Paterson; Mark Clemons; Elizabeth C Dees; James N Ingle; Carla I Falkson; William E Barlow; Gabriel N Hortobagyi; Julie R Gralow
Journal:  Support Care Cancer       Date:  2020-09-15       Impact factor: 3.603

Review 7.  Interventions for managing medication-related osteonecrosis of the jaw.

Authors:  Natalie H Beth-Tasdogan; Benjamin Mayer; Heba Hussein; Oliver Zolk
Journal:  Cochrane Database Syst Rev       Date:  2017-10-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.